The global respiratory biologics sales are estimated to be worth US$ 8154.6 million in 2024. The market is expected to reach US$ 42,319.9 million by 2034. It is projected to surge at a CAGR of 17.9% in the forecast period 2024 to 2034.
Globally, respiratory diseases like asthma, COPD, and allergic rhinitis are increasing due to rise in air pollution, smoking, and lifestyle changes, necessitating effective treatments like respiratory biologics. Biotechnology advancements have led to the development of targeted biologics therapies, which focus on specific respiratory disease pathways and offer improved efficacy and safety compared to traditional treatments.
The treatment of respiratory diseases is shifting toward respiratory biologics, offering targeted approaches to control symptoms, reduce exacerbations, and enhance patients' quality of life compared to conventional methods. The rise of personalized medicine in respiratory care is influencing the development of new biologics and diagnostics to cater to individual patient's specific genetic makeup and disease characteristics.
| Attributes | Key Insights |
|---|---|
| Base Value (2023) | US$ 7,248.6 million |
| Estimated Global Respiratory Biologics Market Size (2024E) | US$ 8,154.6 million |
| Projected Respiratory Biologics Market Value (2034F) | US$ 42,319.9 million |
| Value-based CAGR (2024 to 2034) | 17.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global respiratory biologics market recorded a historical CAGR of 29% from 2019 to 2023. Due to rising respiratory disease prevalence and healthcare spending, the market has grown globally, attracting investments from developed and emerging markets.
Market expansion strategies aim to address unmet medical needs in diverse regions. Ongoing research and development efforts involving collaborations between academia, industry, and government have fueled the pipeline of respiratory biologics, exploring new therapeutic targets and mechanisms of action.
A key factor driving the growth of the respiratory biologics market is the increasing incidence of respiratory diseases. Respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and other pulmonary disorders are becoming more commonplace worldwide. This increasing prevalence highlights the pressing need for efficient treatment options. It establishes respiratory biologics as an important and quickly growing area of the pharmaceutical and biotechnology industries.
Biotechnology progress has led to novel biologics, like monoclonal antibodies, which provide more targeted treatments for respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). The market is seeing a shift toward better drug delivery mechanisms, such as sophisticated inhaler devices, to improve patient compliance and treatment outcomes.
Alliances and strategic partnerships between academic institutions and pharmaceutical companies are supporting research and development. These are increasing the development of respiratory biologics. In addition, the aging population and increased incidence of respiratory illnesses worldwide drive the need for these cutting-edge treatments.
The respiratory biologics market is expanding in terms of awareness, education, and accessibility as governments concentrate on healthcare policies and initiatives. These factors are contributing to its overall growth and evolution.
Raising awareness and comprehension of the molecular mechanisms underlying respiratory diseases opens up new opportunities for innovative biologics therapies. The rise of precision medicine, which emphasizes tailored therapeutic approaches, fits in well with respiratory biologics' targeted nature and opens up new development opportunities.
The growing elderly population which is more susceptible to respiratory ailments, drives market growth. Government programmes and policies that support healthcare improve accessibility would also push demand. Research & development, partnerships, and collaborations increase market potential and drive the introduction of new treatments.
Principal Consultant
Mid-sized companies need help in areas like experience, biologics manufacturing infrastructure, and capital, heightening the challenge. Nevertheless, these mid-sized players possess a distinctive advantage in their capacity for focused efforts, particularly within niche therapeutic areas and cutting-edge technologies.
The high cost of biologics therapies for respiratory diseases is set to restrict access for some patients, especially those without adequate insurance coverage or reimbursement programs. Respiratory biologics are limited by insurance coverage, formulary restrictions, and reimbursement policies, with payers imposing strict eligibility criteria for patients with severe disease or treatment failure.
The table below shows the estimated growth rates of the five leading countries. China, France, and the United States are set to record high CAGRs of 18.9%, 16.3%, and 13.7%, respectively, through 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 13.7% |
| China | 18.9% |
| Japan | 10.1% |
| Germany | 13.7% |
| France | 16.3% |
The United States is expected to exhibit a CAGR of 13.7% throughout the forecast period. Patient and healthcare provider awareness about the benefits of respiratory biologics therapy is growing. It is taking place through education initiatives, advocacy groups, and disease awareness campaigns, which is set to significantly boost market growth and treatment adherence.
The United States is home to several cutting-edge biotechnology and pharmaceutical enterprises. These companies make significant investments in research and development, which results in identifying and releasing innovative respiratory biologics.
China is expected to grow at a CAGR of 18.9% by 2034. China is becoming a key force in the respiratory biologics market because of its rapidly developing healthcare infrastructure and rising awareness of respiratory disorders.
The demand for cutting-edge treatments is increasing due to the rising prevalence of diseases, including COPD and asthma. The market is also growing because of the government's efforts to improve healthcare access and concentrate on developing biotechnology.
China presents a sizable market for respiratory biologics due to its aging population and growing healthcare awareness. Both local and foreign companies are drawn to the area to take advantage of this potential.
Germany is expected to surge at a CAGR of 13.7% during the forecast period. Germany's strong healthcare system, huge research resources, and focus on innovative treatments are driving the country's respiratory biologics industry.
With Germany's dedication to innovation and first-rate healthcare, the nation is well-positioned to advance respiratory biologics. Germany creates an atmosphere favorable to developing and using innovative biological medicines for respiratory disorders, propelling growth in this rapidly expanding healthcare industry.
Japan is expected to surge at a CAGR of 10.1% by 2034. Japan faces a growing burden of respiratory conditions like asthma, COPD, and allergic rhinitis, necessitating the need for effective treatment options, including respiratory biologics.
Respiratory biologics in Japan offer targeted treatment options for severe or difficult-to-treat respiratory conditions, providing better symptom control and reducing exacerbations compared to traditional medications. Japan's respiratory biologics market is growing due to efforts to improve patient access and affordability, including patient assistance programs and negotiated pricing agreements.
France is projected to rise at 16.3% CAGR during the forecast period. The biotechnology sector in France is fostering innovation in respiratory biologics through research and development, resulting in novel molecules, improved delivery devices, and advanced diagnostic tools for personalized patient treatment.
The government is a key regulatory body responsible for overseeing respiratory biologics therapies' approval and post-market surveillance, significantly influencing their development timelines and commercialization strategies in France. France's respiratory biologics market faces fierce competition from pharmaceutical companies, influenced by factors like pricing strategies, market share, and product differentiation.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below shows the intravenous segment dominating by route of administration. It is set to hold a market share of 67.0% in 2024. Based on sales channels, the hospital segment is anticipated to generate a dominant share through 2024. It is likely to generate a share of 44.0% in 2024.
| Segment | Market Share (2024) |
|---|---|
| Intravenous (Route of Administration) | 67.0% |
| Hospital (Sales Channel) | 44.0% |
Respiratory biologics are in high demand because of the growing prevalence of asthma and its profound impact on patients' lives. These cutting-edge therapies effectively relieve asthma by addressing its underlying causes.
Respiratory biologics provide accurate solutions in response to the growing emphasis on individualized therapy, fueling the market's expansion. Owing to their special capacity to target particular pathways, biologics play a pivotal role in respiratory treatment, particularly given the intricate nature of managing asthma.
With their robust infrastructure and resources, hospitals are adept at delivering comprehensive respiratory care services. This includes the diagnosis, treatment, and management of respiratory conditions.
Specialized respiratory care units, dedicated pulmonary function testing labs, and teams of pulmonologists, respiratory therapists, and other healthcare professionals operate within these facilities. Their collective expertise is pivotal in effectively managing respiratory diseases, positioning hospitals as key contributors to the respiratory biologics market.
Respiratory biologics companies are investing heavily in respiratory biologics research & development to advance scientific understanding, expand treatment options, and gain market competitiveness.
For instance
The market was valued at US$ 7,248.6 million in 2023.
The market is set to reach US$ 42,319.9 million by 2034.
The asthma segment by disease indication is set to hold an 82.3% share in 2024.
Demand for the market increased at a 29% CAGR from 2019 to 2023.
The market is expected to reach US$ 8,154.6 million.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 4. Value-Added Insights 4.1. Product Adoption Analysis 4.2. Disease Epidemiology, By Key Countries 4.3. Regulatory Scenario 4.3.1. Regulatory Frameworks in United States 4.3.2. Regulatory Frameworks in Canada 4.3.3. Regulatory Frameworks in Europe 4.3.4. Regulatory Frameworks in China 4.3.5. Regulatory Frameworks in Japan 4.3.6. Regulatory Frameworks in India 4.4. Reimbursement Landscape 4.5. PESTEL Analysis 4.6. Porter’s Analysis 4.7. Value Chain Analysis 4.8. Unmet Needs and Opportunities 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure 5.1.2. R&D Funding Outlook, By Region 5.1.3. R&D Funding Outlook, By Country 5.1.4. Global Biologics Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Growing Prevalence of Respiratory Diseases 5.2.2. Increasing Focus on Personalized Medicine 5.2.3. Rising Demand for Generic and Biologicss 5.2.4. Regulatory Changes and Compliance Requirements 5.2.5. Globalization of Pharmaceutical Supply Chains 5.2.6. Emerging Markets and Untapped Opportunities 5.2.7. Shift Towards Patient-Centric Care 5.2.8. Growing Demand for Combination Therapies 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 6.1. Historical Market Value (US$ million) Analysis, 2019 to 2023 6.2. Current and Future Market Value (US$ million) Projections, 2024 to 2034 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ million) Analysis By Disease Indication, 2019 to 2023 7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Disease Indication, 2024 to 2034 7.3.1. Asthma 7.3.1.1. Moderate to Severe Asthma 7.3.1.2. Severe Asthma 7.3.1.3. Severe Eosinophilic Asthma 7.3.2. Chronic Rhinosinasitis 7.3.3. Hypereosinophilic Syndrome 7.4. Market Attractiveness Analysis By Disease Indication 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ million) By Route of Administration, 2019 to 2023 8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Route of Administration, 2024 to 2034 8.3.1. Intravenous 8.3.2. Subcuteneous 8.4. Market Attractiveness Analysis By Route of Administration 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Sales Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ million) By Sales Channel, 2019 to 2023 9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Sales Channel, 2024 to 2034 9.3.1. Hospitals 9.3.2. Specialty Clinics 9.3.3. Retail Pharmacies 9.3.4. Mail Order Pharmacies 9.4. Market Attractiveness Analysis By Sales Channel 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ million) Trend Analysis by Region, 2019 to 2023 10.3. Current and Future Market Size (US$ million) Analysis and Forecast by Region, 2024 to 2034 10.3.1. North America 10.3.2. Latin America 10.3.3. East Asia 10.3.4. South Asia & Pacific 10.3.5. Western Europe 10.3.6. Eastern Europe 10.3.7. Middle East & Africa 10.4. Market Attractiveness Analysis by Region 11. North America Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 11.1. Introduction 11.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 11.3.1. By Country 11.3.1.1. United States 11.3.1.2. Canada 11.3.1.3. Mexico 11.3.2. By Disease Indication 11.3.3. By Route of Administration 11.3.4. By Sales Channel 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Disease Indication 11.4.3. By Route of Administration 11.4.4. By Sales Channel 11.5. Market Trends 11.6. Drivers & Restraints Impact Analysis 11.7. Country-Wise Analysis 11.7.1. United States Market Analysis 11.7.1.1. Introduction 11.7.1.2. Market Analysis and Forecast by Market Taxonomy 11.7.1.2.1. By Disease Indication 11.7.1.2.2. By Route of Administration 11.7.1.2.3. By Sales Channel 11.7.2. Canada Market Analysis 11.7.2.1. Introduction 11.7.2.2. Market Analysis and Forecast by Market Taxonomy 11.7.2.2.1. By Disease Indication 11.7.2.2.2. By Route of Administration 11.7.2.2.3. By Sales Channel 11.7.3. Mexico Market Analysis 11.7.3.1. Introduction 11.7.3.2. Market Analysis and Forecast by Market Taxonomy 11.7.3.2.1. By Disease Indication 11.7.3.2.2. By Route of Administration 11.7.3.2.3. By Sales Channel 12. Latin America Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 12.1. Introduction 12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Chile 12.3.1.3. Rest of Latin America 12.3.2. By Disease Indication 12.3.3. By Route of Administration 12.3.4. By Sales Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Disease Indication 12.4.3. By Route of Administration 12.4.4. By Sales Channel 12.5. Market Trends 12.6. Drivers & Restraints Impact Analysis 12.7. Country-Wise Analysis 12.7.1. Brazil Market Analysis 12.7.1.1. Introduction 12.7.1.2. Market Analysis and Forecast by Market Taxonomy 12.7.1.2.1. By Disease Indication 12.7.1.2.2. By Route of Administration 12.7.1.2.3. By Sales Channel 12.7.2. Chile Market Analysis 12.7.2.1. Introduction 12.7.2.2. Market Analysis and Forecast by Market Taxonomy 12.7.2.2.1. By Disease Indication 12.7.2.2.2. By Route of Administration 12.7.2.2.3. By Sales Channel 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13.1. Introduction 13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 13.3.1. By Country 13.3.1.1. China 13.3.1.2. Japan 13.3.1.3. South Korea 13.3.2. By Disease Indication 13.3.3. By Route of Administration 13.3.4. By Sales Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Disease Indication 13.4.3. By Route of Administration 13.4.4. By Sales Channel 13.5. Market Trends 13.6. Drivers & Restraints Impact Analysis 13.7. Country-Wise Analysis 13.7.1. China Market Analysis 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Disease Indication 13.7.1.2.2. By Route of Administration 13.7.1.2.3. By Sales Channel 13.7.2. Japan Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Disease Indication 13.7.2.2.2. By Route of Administration 13.7.2.2.3. By Sales Channel 13.7.3. South Korea Market Analysis 13.7.3.1. Introduction 13.7.3.2. Market Analysis and Forecast by Market Taxonomy 13.7.3.2.1. By Disease Indication 13.7.3.2.2. By Route of Administration 13.7.3.2.3. By Sales Channel 14. South Asia & Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. India 14.3.1.2. ASEAN Countries 14.3.1.3. Australia & New Zealand 14.3.1.4. Rest of South Asia & Pacific 14.3.2. By Disease Indication 14.3.3. By Route of Administration 14.3.4. By Sales Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Disease Indication 14.4.3. By Route of Administration 14.4.4. By Sales Channel 14.5. Market Trends 14.6. Drivers & Restraints Impact Analysis 14.7. Country-Wise Analysis 14.7.1. India Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Disease Indication 14.7.1.2.2. By Route of Administration 14.7.1.2.3. By Sales Channel 14.7.2. ASEAN Countries Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Disease Indication 14.7.2.2.2. By Route of Administration 14.7.2.2.3. By Sales Channel 14.7.3. Australia & New Zealand Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Disease Indication 14.7.3.2.2. By Route of Administration 14.7.3.2.3. By Sales Channel 15. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. France 15.3.1.3. Spain 15.3.1.4. Italy 15.3.1.5. BENELUX 15.3.1.6. Nordic Countries 15.3.1.7. United Kingdom 15.3.1.8. Rest of Western Europe 15.3.2. By Disease Indication 15.3.3. By Route of Administration 15.3.4. By Sales Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Disease Indication 15.4.3. By Route of Administration 15.4.4. By Sales Channel 15.5. Market Trends 15.6. Drivers & Restraints Impact Analysis 15.7. Country-Wise Analysis 15.7.1. Germany Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Disease Indication 15.7.1.2.2. By Route of Administration 15.7.1.2.3. By Sales Channel 15.7.2. France Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Disease Indication 15.7.2.2.2. By Route of Administration 15.7.2.2.3. By Sales Channel 15.7.3. Spain Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Disease Indication 15.7.3.2.2. By Route of Administration 15.7.3.2.3. By Sales Channel 15.7.4. Italy Republic Market Analysis 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Disease Indication 15.7.4.2.2. By Route of Administration 15.7.4.2.3. By Sales Channel 15.7.5. BENELUX Republic Market Analysis 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Disease Indication 15.7.5.2.2. By Route of Administration 15.7.5.2.3. By Sales Channel 15.7.6. Nordic Countries Market Analysis 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Disease Indication 15.7.6.2.2. By Route of Administration 15.7.6.2.3. By Sales Channel 15.7.7. United Kingdom Market Analysis 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Disease Indication 15.7.7.2.2. By Route of Administration 15.7.7.2.3. By Sales Channel 16. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. Poland 16.3.1.2. Hungary 16.3.1.3. Russia 16.3.1.4. Rest of Eastern Europe 16.3.2. By Disease Indication 16.3.3. By Route of Administration 16.3.4. By Sales Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Disease Indication 16.4.3. By Route of Administration 16.4.4. By Sales Channel 16.5. Market Trends 16.6. Drivers & Restraints Impact Analysis 16.7. Country-Wise Analysis 16.7.1. Poland Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Disease Indication 16.7.1.2.2. By Route of Administration 16.7.1.2.3. By Sales Channel 16.7.2. Hungary Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Disease Indication 16.7.2.2.2. By Route of Administration 16.7.2.2.3. By Sales Channel 16.7.3. Russia Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Disease Indication 16.7.3.2.2. By Route of Administration 16.7.3.2.3. By Sales Channel 17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 17.3.1. By Country 17.3.1.1. Saudi Arabia 17.3.1.2. Türkiye 17.3.1.3. South Africa 17.3.1.4. Other African Union 17.3.1.5. Rest of Middle East and Africa 17.3.2. By Disease Indication 17.3.3. By Route of Administration 17.3.4. By Sales Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Disease Indication 17.4.3. By Route of Administration 17.4.4. By Sales Channel 17.5. Market Trends 17.6. Drivers & Restraints Impact Analysis 17.7. Country-Wise Analysis 17.7.1. Saudi Arabia Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Disease Indication 17.7.1.2.2. By Route of Administration 17.7.1.2.3. By Sales Channel 17.7.2. Türkiye Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Disease Indication 17.7.2.2.2. By Route of Administration 17.7.2.2.3. By Sales Channel 17.7.3. South Africa Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Disease Indication 17.7.3.2.2. By Route of Administration 17.7.3.2.3. By Sales Channel 17.7.4. Other African Union Market Analysis 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Disease Indication 17.7.4.2.2. By Route of Administration 17.7.4.2.3. By Sales Channel 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Share Analysis of Top Players (%) 18.3. Market Presence Analysis 18.3.1. Regional footprint of Players 18.3.2. Channel Foot Print by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Branding and Promotional Strategies, By Key Players 19.3. Key Development Analysis 19.4. Competition Deep Dive (Tentative List) 19.4.1. GSK plc. 19.4.1.1. Overview 19.4.1.2. Inhalation Platform Portfolio 19.4.1.3. Key Financials 19.4.1.4. SWOT Analysis 19.4.1.5. Key Developments 19.4.1.6. Sales Footprint 19.4.1.7. Strategy Overview 19.4.1.7.1. Marketing Strategy 19.4.1.7.2. Inhalation Platform Strategy 19.4.1.7.3. Channel Strategy 19.4.2. AstraZeneca 19.4.3. Sanofi and Regeneron Pharmaceuticals, Inc. 19.4.4. Genentech USA, Inc. 19.4.5. Teva Respiratory, LLC. 19.4.6. Novartis Pharmaceuticals Corporation 19.4.7. GlaxoSmithKline 19.4.8. Novartis 19.4.9. Roche 19.4.10. Boehringer Ingelheim 19.4.11. Regeneron Pharmaceuticals 19.4.12. Merck & Co. 19.4.13. Johnson & Johnson 19.4.14. Amgen 19.4.15. Biogen 19.4.16. Vertex Pharmaceuticals 19.4.17. Genentech (a member of the Roche Group) 19.4.18. AbbVie 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Respiratory Biologics Market
